NCT00085462View on ClinicalTrials.gov

Gene-Modified White Blood Cells Followed By Interleukin-2 and Vaccine Therapy in Treating Patients With Metastatic Melanoma

PHASE1CompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

May 31, 2004

Primary Completion Date

May 31, 2007

Study Completion Date

September 30, 2008

Conditions

Melanoma (Skin)

Interventions

BIOLOGICAL

aldesleukin

BIOLOGICAL

filgrastim

BIOLOGICAL

gp100-fowlpox vaccine

BIOLOGICAL

therapeutic autologous lymphocytes

BIOLOGICAL

therapeutic tumor infiltrating lymphocytes

DRUG

cyclophosphamide

DRUG

fludarabine phosphate

Trial Locations (2)

20892-1182

Warren Grant Magnuson Clinical Center - NCI Clinical Trials Referral Office, Bethesda

20892-1201

NCI - Surgery Branch, Bethesda

All Listed Sponsors

collaborator

National Cancer Institute (NCI)

NIH

lead

National Institutes of Health Clinical Center (CC)

NIH

NCT00085462 - Gene-Modified White Blood Cells Followed By Interleukin-2 and Vaccine Therapy in Treating Patients With Metastatic Melanoma | Biotech Hunter | Biotech Hunter